TY - JOUR
T1 - Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines
T2 - A Worldwide Review
AU - Kroumpouzos, George
AU - Paroikaki, Maria Eleni
AU - Yumeen, Sara
AU - Bhargava, Shashank
AU - Mylonakis, Eleftherios
N1 - Funding Information:
Conflicts of Interest: The authors declare no conflict of interest. Eleftherios Mylonakis was involved in clinical trials on COVID-19. These trials were supported by Regeneron, NIH, and SciClone Pharmaceuticals, Inc. All funds were given to the institution, and Eleftherios Mylonakis received no direct funds.
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/3
Y1 - 2022/3
N2 - Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines world-wide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca– Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.
AB - Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines world-wide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca– Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.
KW - COVID-19 vaccine
KW - Chilblains
KW - Delayed hypersensitivity reaction
KW - Herpes zoster
KW - MRNA vaccine
KW - Morbilliform
KW - Rash
KW - Skin reaction
KW - Urticaria
UR - http://www.scopus.com/inward/record.url?scp=85126331874&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126331874&partnerID=8YFLogxK
U2 - 10.3390/microorganisms10030624
DO - 10.3390/microorganisms10030624
M3 - Review article
AN - SCOPUS:85126331874
SN - 2076-2607
VL - 10
JO - Microorganisms
JF - Microorganisms
IS - 3
M1 - 624
ER -